Headquartered in Orlando, FL Fiscal year ends December NASDAQ: IRMD iradimed.com
IRADIMED CORPORATION designs, manufactures, markets and distributes medical devices built for use inside the MRI environment, along with accessories, disposables and related services.
Its core products are:
- MRidium MRI-compatible IV infusion pump systems (models 3860 and the next-generation 3870). The company describes itself as the only known provider of a non-magnetic IV infusion pump designed to be safe during MRI procedures. The pumps use a non-magnetic ultrasonic motor and non-ferrous parts to deliver anesthesia and other IV fluids to critically ill patients and sedated children and infants during scans.
- The 3880 MRI-compatible patient vital signs monitoring system, which operates in magnetic fields up to 30,000 gauss. It offers wireless ECG, wireless SpO2 using Masimo algorithms, non-magnetic respiratory CO2, invasive and non-invasive blood pressure, temperature, and an optional multi-gas anesthetic agent unit.
- Ferro magnetic detection systems.
The company earns recurring revenue from disposables, extended maintenance agreements and services.
It is currently ramping production of the 3870 pump. Hospitals are replacing older pumps and increasingly standardizing on a four-pump 'quad stack' configuration. Sales are predominantly domestic, at 82% of Q3 2026 revenue, with a growing international share. The company pays a regular quarterly cash dividend. Updated
Management now guides Q4 to $25.0 million to $26.5 million, a $100 million annualized run rate, after record revenue broke a two-quarter slide. Over 70% of pump bookings were quad-stack units that double infusion capacity per MRI suite, with EPS meeting expectations.
IRADIMED CORPORATION designs, manufactures, markets and distributes medical devices built for use inside the MRI environment, along with accessories, disposables and related services. Its core products are: - MRidium MRI-compatible IV infusion pump systems (models 3860 and the next-generation 3870).
The Wall Street consensus 12-month price target for IRMD is $118.00.